PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944461
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944461
Angiographic Catheters Market size was valued at US$ 1,650.09 Million in 2024, expanding at a CAGR of 8.10% from 2025 to 2032.
The angiographic catheters market includes catheters used in angiographic procedures, where contrast is injected into blood vessels to visualize vessel anatomy under imaging, usually fluoroscopy. These devices are common in coronary, peripheral, neuro, and visceral procedures, and selection usually depends on practical performance factors such as trackability, torque control, kink resistance, radiopacity, and compatibility with guidewires and access sheaths. Demand is closely tied to the number of diagnostic and interventional vascular procedures, which is supported by the large burden of cardiovascular disease and risk factors such as diabetes and hypertension.
Hospitals and cath labs also prefer products that help improve workflow and reduce procedure time, while keeping complication risk low. Hence, supplier reliability, consistent product quality, and availability in high-volume settings matter alongside clinical performance. Product development trends include lower-profile catheter designs, improved tip shapes for stable vessel engagement, and coatings that help navigation through complex anatomy, which can support smoother procedures and potentially shorter recovery when less invasive access approaches are used.
Angiographic Catheters Market- Market Dynamics
Large Cardiovascular Disease and Diabetes Base Keeping Angiography Demand High
A major driver for angiographic catheters is the large and ongoing burden of cardiovascular disease, since angiography is still a common step for diagnosing vessel blockages and planning catheter-based treatment. The scale of the patient need remains high globally; According to the World Health Organization (WHO), cardiovascular diseases cause around 17.9 million deaths each year, keeping focus on earlier detection and management of coronary and vascular conditions. The U.S. numbers also show a large clinical workload for hospitals and cath labs; According to Centers for Disease Control and Prevention (CDC), heart disease led to 695,000+ deaths in 2021, and stroke accounted for 160,000+ deaths in 2021, which supports steady demand for vascular imaging and follow-up procedures. Risk factors linked to vascular disease add more volume over time. According to CDC, diabetes affected 37.3 million people in the United States based on recent national estimates, and diabetes is closely tied to peripheral artery disease and coronary disease that often require angiographic evaluation. This overall disease and risk-factor base keeps procedure volumes stable and encourages procurement of catheters that support predictable performance, smooth navigation, and efficient contrast delivery in high-throughput settings.
Angiography demand is staying strong mainly because coronary disease and related risk factors keep procedure volumes high in hospital cath labs. The clinical burden in the U.S. remains large; According to Centers for Disease Control and Prevention (CDC), heart disease caused 695,000+ deaths in 2021, which keeps diagnostic workups and treatment planning active for coronary artery disease. Risk-factor growth adds more long-term volume. According to CDC, 37.3 million people in the U.S. were living with diabetes based on recent national estimates, and diabetes is closely linked with coronary and peripheral artery disease where angiographic evaluation is commonly used. In parallel, vascular imaging demand is supported by neurovascular evaluation needs tied to stroke burden; According to CDC, stroke accounted for 160,000+ deaths in 2021, and the disability and follow-up needs associated with stroke keep imaging pathways relevant beyond acute care.
At a global level, the overall base of cardiovascular conditions remains a constant driver for angiography services. According to World Health Organization (WHO), cardiovascular diseases lead to around 17.9 million deaths each year, which supports continued investment in vascular diagnostic capacity and steady purchasing of angiographic consumables needed for daily cath lab workflow.
Angiographic Catheters Market- Geographical Insights
Angiographic catheter demand tends to be highest in regions where cardiovascular care is well established and cath lab access is widespread, since procedure volumes depend on hospital infrastructure and routine use of vascular imaging in diagnosis and treatment planning. The baseline need remains large worldwide; According to the World Health Organization (WHO), cardiovascular diseases cause around 17.9 million deaths each year, which keeps coronary and peripheral vessel assessment as a regular part of care pathways. Neurovascular imaging also stays relevant because stroke creates ongoing diagnostic and follow-up needs; According to Centers for Disease Control and Prevention (CDC), stroke accounted for 160,000+ deaths in 2021 in the U.S., showing the scale of vascular conditions tied to imaging and intervention planning. Mature markets typically show steady demand due to established reimbursement and high chronic disease prevalence, while growth markets benefit from expanding hospital capacity and rising diabetes and hypertension rates.
United States Angiographic Catheters Market- Country Insights
The United States is one of the strongest country markets because the clinical burden is high and the hospital ecosystem supports consistent angiography and intervention workflows. According to Centers for Disease Control and Prevention (CDC), heart disease caused 695,000+ deaths in 2021, which aligns with sustained use of coronary imaging and related catheter-based procedures. Risk factors that drive future case volumes remain significant; According to CDC, 37.3 million people in the U.S. were living with diabetes based on recent national estimates, and diabetes is closely linked with coronary and peripheral artery disease, where angiographic evaluation is common. These factors support regular purchasing of angiographic catheters across hospitals and cath labs, with supply consistency and predictable performance becoming key requirements to avoid procedure delays.
Competition is led by large cardiovascular device companies and specialized catheter manufacturers, and differentiation is usually based on product range, handling characteristics, and service reliability. Boston Scientific Corporation, Medtronic plc, and Abbott Laboratories are commonly associated with broad cardiology portfolios and strong hospital relationships that support standardization in cath labs. Terumo Corporation, Cordis Corporation, and Asahi Intecc Co., Ltd. are often linked with catheter and guidewire expertise, especially where trackability and navigation in complex anatomy are important. Becton, Dickinson and Company, Teleflex Incorporated, Cook Group Incorporated, Merit Medical Systems, Inc., and AngioDynamics, Inc. are frequently referenced for wide distribution and strong presence across interventional procedure categories. Procurement decisions typically focus on consistent catheter performance, compatibility with existing guidewires and access systems, vendor training support, and dependable availability, since shortages and variability can directly affect procedure scheduling and total procedure cost.
In May 2025, Mayo Clinic, a nonprofit academic medical center and research hospital, reported first-in-human early feasibility results for a novel self-centering catheter designed to help retrograde crossing of a severely stenotic aortic valve during transfemoral TAVR, stating the device was used in 20 patients with no adverse events and was developed in collaboration with Boston Scientific to improve crossing efficiency and potentially reduce radiation exposure, procedure time, and embolic risk.
In February 2024, Koninklijke Philips N.V., a healthcare technology company, introduced LumiGuide powered by Fiber Optic RealShape (FORS) to navigate devices in blood vessels using light instead of X-ray, highlighting early use in late 2023 at Maastricht University Medical Center and the University of Alabama at Birmingham, with initial availability to major Aortic Centers of Excellence in the U.S. and Europe and reporting experience across 900+ patients at nine centers, including one site's cohort comparison showing 37% shorter complex aortic procedure time and 56% lower radiation exposure (DAP) versus X-ray guidance.
In January 2020, TriSalus Life Sciences, Inc., an oncology-focused medical device company, launched the TriNav Infusion System using Pressure-Enabled Drug Delivery (PEDD) with SmartValve technology to improve therapeutic delivery into solid tumors such as HCC and liver metastases, citing a retrospective single-center study where objective response was 100% with PEDD versus 76.5% with standard end-hole microcatheters and tumor necrosis-based pathological response was 88.8% versus 33.8%, and noting the device received CMS transitional pass-through payment effective January 1, 2020 under the Hospital Outpatient and ASC payment systems.